Last reviewed · How we verify
Liraglutid
Liraglutid is a Small molecule drug developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It is currently FDA-approved for Diabetes mellitus type 2, Weight loss. Also known as: metformin.
Liraglutide, marketed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, is a GLP-1 receptor agonist primarily indicated for the treatment of type 2 diabetes mellitus. A key strength of Liraglutide is its well-established mechanism and market presence, with a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent expiration approaches, which could impact market share and revenue.
At a glance
| Generic name | Liraglutid |
|---|---|
| Also known as | metformin |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Target | Glucagon-like peptide 1 receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus type 2
- Weight loss
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia (with sulfonylurea, glucose <54 mg/dL)
- Erythema at injection site
- Pruritus at injection site
- Rash at injection site
Serious adverse events
- Severe hypoglycemia (requiring assistance, with sulfonylurea)
Key clinical trials
- Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (PHASE1)
- Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) (PHASE4)
- Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid (PHASE3)
- Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes (PHASE4)
- Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy. (NA)
- The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liraglutid CI brief — competitive landscape report
- Liraglutid updates RSS · CI watch RSS
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School portfolio CI
Frequently asked questions about Liraglutid
What is Liraglutid?
What is Liraglutid used for?
Who makes Liraglutid?
Is Liraglutid also known as anything else?
What development phase is Liraglutid in?
What are the side effects of Liraglutid?
What does Liraglutid target?
Related
- Target: All drugs targeting Glucagon-like peptide 1 receptor
- Manufacturer: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Diabetes mellitus type 2
- Indication: Drugs for Weight loss
- Also known as: metformin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing